Development of a Doxazosin and Finasteride Transdermal System for Combination Therapy of Benign Prostatic Hyperplasia

    August 2013 in “ Journal of pharmaceutical sciences ”
    Carolina Gonçalves Pupe, Flávia Almada do Carmo, Valéria Pereira de Sousa, Mariana Canuto Melo de Sousa Lopes, Bárbara Abrahim-Vieira, António J. Ribeiro, Francisco Veiga, Carlos Rangel Rodrigues, Cristina Padula, Patrizia Santi, Lúcio Mendes Cabral
    New to Finasteride? There is a guide in the encyclopedia. Read the guide →
    Image
    Studysummary This study found that a transdermal delivery system using 3% azone and P407 gel may enhance the skin permeation of doxazosin and finasteride for treating benign prostatic hyperplasia.
    Our plain-language summary. Not medical advice or a treatment recommendation. Consult a qualified healthcare professional before changing treatment. Full disclaimer
    In 2013, researchers developed a transdermal delivery system for the combination therapy of benign prostatic hyperplasia using doxazosin, an α-1 adrenergic antagonist, and finasteride, a 5-α reductase inhibitor. They prepared doxazosin base (DB) from doxazosin mesylate and characterized it along with finasteride using X-ray powder diffraction (XRD), differential scanning calorimetry (DSC), and nuclear magnetic resonance (NMR). In vitro studies were conducted to evaluate the effectiveness of permeation enhancers and gelling agents in facilitating drug permeation through pig ear epidermis. The study found that 3% (w/w) azone was the most effective permeation enhancer and that Poloxamer 407 (P407) gel was superior to hydroxypropyl cellulose (HPC) gel in reducing lag time and increasing permeation of both drugs, likely due to its interaction with the stratum corneum. This transdermal system could potentially improve patient adherence and allow for easier dose adjustment in the treatment of benign prostatic hyperplasia.
    Discuss this study in the Community →

    Research cited in this study

    1 / 1 results